Experimental drug aims to rebuild immunity against fatal brain virus
NCT ID NCT04781309
First seen Nov 01, 2025 · Last updated May 15, 2026 · Updated 27 times
Summary
This study tested a drug called NT-I7 in 12 adults with progressive multifocal leukoencephalopathy (PML), a rare and serious brain infection caused by a virus. People with PML often have low levels of immune cells (lymphopenia), making it hard to fight the infection. The goal was to see if NT-I7 could safely increase those immune cells and help control the disease. Participants received up to 3 injections and were followed for 12 to 19 months.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
National Institutes of Health Clinical Center
Bethesda, Maryland, 20892, United States
Conditions
Explore the condition pages connected to this study.